A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects

Summary

1. To evaluate the safety and tolerability of CU-40101 liniment as a single and multiple topical application in adult male androgenic alopecia subjects； 2. To evaluate the pharmacokinetic (PK) characteristics of CU-40101 liniment administered as a single and multiple topical skin application in adult male subjects with androgenic alopecia.

Timeline

Start

2022-08-15

Primary completion

2023-11-15

Completion

2024-02-22

Outcome

Met primary endpoint

release “CU-40101 (topical small molecule thyroid hormone receptor agonist liniment) conducted in China for the treatment of androgenetic alopecia reached primary endpoint.” cutiatx.com ↗

Drugs

Indications